Literature DB >> 30370073

Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?

Elisabeth Quoix1, Virginie Westeel2.   

Abstract

Entities:  

Year:  2018        PMID： 30370073      PMCID： PMC6186639          DOI： 10.21037/jtd.2018.08.33

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

Review 1.  Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.

Authors:  Robert Pirker
Journal:  Curr Opin Oncol       Date:  2015-03       Impact factor: 3.645

2.  EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.

Authors:  Robert Pirker
Journal:  Lancet Oncol       Date:  2017-11-20       Impact factor: 41.316

3.  Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

Authors:  Jean-Louis Pujol; Robert Pirker; Thomas J Lynch; Charles A Butts; Rafael Rosell; Frances A Shepherd; Johan Vansteenkiste; Kenneth J O'Byrne; Barbara de Blas; Jim Heighway; Anja von Heydebreck; Nick Thatcher
Journal:  Lung Cancer       Date:  2013-11-16       Impact factor: 5.705

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

5.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Authors:  Luis Paz-Ares; Jörg Mezger; Tudor E Ciuleanu; Jürgen R Fischer; Joachim von Pawel; Mariano Provencio; Andrzej Kazarnowicz; György Losonczy; Gilberto de Castro; Aleksandra Szczesna; Lucio Crino; Martin Reck; Rodryg Ramlau; Ernst Ulsperger; Christian Schumann; Jose Elias A Miziara; Álvaro E Lessa; Mircea Dediu; Beatrix Bálint; Henrik Depenbrock; Victoria Soldatenkova; Raffael Kurek; Fred R Hirsch; Nick Thatcher; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-02-18       Impact factor: 41.316

6.  Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Authors:  Roy S Herbst; Mary W Redman; Edward S Kim; Thomas J Semrad; Lyudmila Bazhenova; Gregory Masters; Kurt Oettel; Perry Guaglianone; Christopher Reynolds; Anand Karnad; Susanne M Arnold; Marileila Varella-Garcia; James Moon; Philip C Mack; Charles D Blanke; Fred R Hirsch; Karen Kelly; David R Gandara
Journal:  Lancet Oncol       Date:  2017-11-20       Impact factor: 41.316

7.  Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Authors:  R Rosell; G Robinet; A Szczesna; R Ramlau; M Constenla; B C Mennecier; W Pfeifer; K J O'Byrne; T Welte; R Kolb; R Pirker; A Chemaissani; M Perol; M R Ranson; P A Ellis; K Pilz; M Reck
Journal:  Ann Oncol       Date:  2007-10-17       Impact factor: 32.976

8.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

9.  Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

Authors:  Charles A Butts; David Bodkin; Edward L Middleman; Craig W Englund; David Ellison; Yasmin Alam; Harvey Kreisman; Peter Graze; James Maher; Helen J Ross; Peter M Ellis; William McNulty; Edward Kaplan; Virginie Pautret; Martin R Weber; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

Review 10.  ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; M J Piccart; J Bogaerts; J Tabernero; N J Latino; E G E de Vries
Journal:  ESMO Open       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.